Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

Tarih
2011
Yazar
CARTWRIGHT, R.
GATTORNO, M.
SMITH, J.
LESLIE, K. S.
JIMENEZ, S.
MORELL-DUBOIS, S.
DAVIS, N.
PATEL, N.
WIDMER, A.
PREISS, R.
Lachmann, H. J.
Gül, Ahmet
KUEMMERLE-DESCHNER, Jasmin B.
HACHULLA, E.
Hawkins, P. N.
TRAN, T. A.
Bader-Meunier, B.
HOYER, J.
Üst veri
Tüm öğe kaydını göster
Özet
Objective Longer-term effects of prolonged selective interleukin-1 beta blockade with canakinumab were evaluated in the largest cohort of cryopyrin-associated periodic syndrome (CAPS) patients studied to date.
Bağlantı
http://hdl.handle.net/20.500.12627/93452
https://doi.org/10.1136/ard.2011.152728
Koleksiyonlar